Skip to content
GLP-1 Scorecard
Menu
Site position #348

Bliv

Published by GLP-1 ScorecardUpdated

Bliv is a telehealth provider selling personalized compounded GLP-1 programs.

Visit BlivWe may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Semaglutide
$116/mo (as low as, varies by plan and eligibility, compounded)
Tirzepatide
$199/mo (as low as, varies by plan and eligibility, compounded)
Coverage
Coverage not published
Brand-name
Not confirmed

Weigh Bliv against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives. If you are considering a compounded option, read about whether compounded semaglutide is legit and safe.

Factor breakdown

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and policies may differ from those used in the marks. See the methodology.

Cost value71/100
Dose & formulation64/100
Clinical oversight55/100
Labs & monitoring53/100
Fulfillment65/100
Contract terms45/100

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

What to consider

  • The advertised rates are 'as low as' figures footnoted 'based on plan structure and eligibility', and the plan selector sits behind the medical intake — the rate you are offered is not knowable before you hand over a medical history
  • A $24.99 provider consultation fee is charged on top, and the refund policy deducts $200 for 'clinical coordination and account setup'
  • The homepage advertises 'no long-term commitments or cancellation fees' while the terms require the membership fee to be paid 'in a single sum', call it non-refundable and refer to a 'Membership Term'
  • The only figure smaller than the advertised rate is a $29 CareCredit/Klarna installment, which is a financing payment rather than the price of a month of medication
  • FDA issued Bliv Wellness LLC dba Bliv a warning letter in February 2026; the letter is public in FDA's warning-letter database

Bottom line — Grade C

Best for: Shoppers who want mainstream telehealth GLP-1 access.

Site position #348 of 541. Commercial relationships affect placement, not the score. See our featured provider, CoreAge Rx (#1), for comparison.

FDAWarning letter issued to Bliv Wellness LLC dba Bliv in February 2026. See the FDA warning-letter database.

Closest here

The rankings grading nearest Bliv — the realistic shortlist.

The 18 rankings nearest this one

View full scorecard rankings →

Pricing/verification reflect Bliv's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Bliv's site. Not medical advice; see our disclosure.

← Back to the scorecard